Cardio-oncology: A new discipline in medicine to lead us into truly integrative care

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 359-361

  Clarke, Ellen ^a   Lenihan, Daniel ^b  

^a Unitec House   (United Kingdom)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Advanced imaging; Biomarkers; Cardio oncology; Cardiotoxicity

Indexed keywords

CANCER SURVIVAL; CANCER THERAPY; CARDIO ONCOLOGY; CARDIOLOGY; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL RESEARCH; EDITORIAL; HUMAN; ONCOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT;

CARDIOLOGY; HUMANS; MEDICAL ONCOLOGY;

EID: 84939458457     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.55     Document Type: Editorial

References (18)

1. Eschenhagen T, Force T, Ewer MS. et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur. J. Heart Fail. 13(1), 1-10 (2011).
2. Parashar S. Building bridges: the emerging field of cardio-oncology. Future Cardiol. 11(4), 377-382 (2015).
3. Jahangir E, Polin NM, Lavie CJ, Fazio S. The link between lipids, statins, and cancer: is there a role for cardio-oncology? Future Cardiol. 11(4), 389-393 (2015).
4. Codón JC, Rosillo Rodríguez SO, López Fernández T. Cardiotoxicity from the cardiologist's perspective. Future Cardiol. 11(4), 425-432 (2015).
5. Storozynsky E. Multimodality assessment and treatment of chemotherapy induced cardiotoxicity Future Cardiol. 11(4), 421-242 (2015).
6. Piper S. Heart failure and chemotherapeutic agents: a review. Future Cardiol. 11(4), 453-470 (2015).
7. Fradley MG, Pinilla-Ibarz J. Arrhythmic complications of tyrosine kinase inhibitors Future Cardiol. 11(4), 395-399 (2015).
8. Salvatorelli E, Menna P, Minotti G. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind. Future Cardiol. 11(4), 363-366 (2015).
9. Beukema JC, Langendijk JA, Muijs CT. Cardiac toxicity in the radiation treatment of oesophageal cancer: an emerging concern. Future Cardiol. 11(4), 367-369 (2015).
10. Barac A. Improving prediction of cardiovascular complications of cancer therapy: what does the future hold? Future Cardiol. 11(4), 383-387 (2015).
11. Khouri MG, Klein MR, Velazquez EJ, Jones LW. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology Future Cardiol. 11(4), 471-484 (2015).
12. Collier P, Koneru S, Tamarappoo B, Griffin B. Cardio-oncology: strain imaging to detect cancer therapeutics-related cardiac dysfunction-are we there yet? Future Cardiol. 11(4), 401-405 (2015).
13. Yu AF, Jones LW. Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training. Future Cardiol. 11(4), 441-452 (2015).
14. Berkman AM, Lakoski SG. The potential of aerobic exercise training in mitigating cardiovascular side effects of cancer therapy. Future Cardiol. 11(4), 407-411 (2015).
15. Mulrooney DA, Duprez D. Caring for cancer survivors-more than just checking the blood pressure and measuring the ejection fraction. Future Cardiol. 11(4), 371-375 (2015).
16. Montoro N, López-Sendón JL. Heart failure years after cancer treatment. Future Cardiol. 11(4), 433-440 (2015).
17. Okwuosa TM, Akhter N, Williams KA, DeCara JM. Building a cardio-oncology program in a small to medium-sized, non-primary cancer center, academic hospital in the United States: challenges and pitfalls. Future Cardiol. 11(4), 413-420 (2015).
18. Lestuzzi C, De Paoli A, Baresic T, Miolo G, Buonadonna A. Malignant cardiac tumors; diagnosis and treatment. Future Cardiol. 11(4), 485-500 (2015).